Nymox Pharmaceutical (NYMX) Trading 5.7% Higher
Nymox Pharmaceutical Corp (NASDAQ:NYMX) traded up 5.7% during mid-day trading on Tuesday . The company traded as high as $2.00 and last traded at $1.86. 573,631 shares changed hands during mid-day trading, an increase of 304% from the average session volume of 141,861 shares. The stock had previously closed at $1.76.
Nymox Pharmaceutical (NASDAQ:NYMX) last released its quarterly earnings results on Monday, August 13th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter. The company had revenue of $0.09 million during the quarter. Nymox Pharmaceutical had a negative net margin of 3,455.58% and a negative return on equity of 4,095.76%.
Several institutional investors have recently added to or reduced their stakes in the company. Brown Advisory Inc. acquired a new position in Nymox Pharmaceutical during the 1st quarter worth approximately $113,000. Bank of America Corp DE grew its holdings in Nymox Pharmaceutical by 648.6% during the 2nd quarter. Bank of America Corp DE now owns 58,623 shares of the biopharmaceutical company’s stock worth $197,000 after acquiring an additional 50,792 shares in the last quarter. Northern Trust Corp grew its holdings in Nymox Pharmaceutical by 8.7% during the 2nd quarter. Northern Trust Corp now owns 272,825 shares of the biopharmaceutical company’s stock worth $916,000 after acquiring an additional 21,828 shares in the last quarter. Finally, BlackRock Inc. grew its holdings in Nymox Pharmaceutical by 2.7% during the 1st quarter. BlackRock Inc. now owns 1,318,707 shares of the biopharmaceutical company’s stock worth $5,578,000 after acquiring an additional 35,035 shares in the last quarter. 7.25% of the stock is currently owned by institutional investors and hedge funds.
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population. It markets NicAlert and TobacAlert test strips that use urine or saliva to detect use of tobacco products. The company also offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease.
See Also: Compound Annual Growth Rate (CAGR)
Receive News & Ratings for Nymox Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nymox Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.